|
Follow-up(months)
| | |
|
Median(range)
|
31(7–103)
| |
|
Age(years)
| | |
|
Median(range)
|
59(22–82)
| |
|
Pretreatment albumin
| | |
|
≥35 g/L
|
173
|
71.2
|
|
<35 g/L
|
70
|
28.8
|
|
Pretreatment CEA
a
| | |
|
≤10 ng/ml
|
186
|
76.5
|
|
>10 ng/ml
|
57
|
23.5
|
|
Differentiation
| | |
|
High
|
24
|
9.9
|
|
Middle
|
198
|
81.5
|
|
Low
|
21
|
8.6
|
|
Sex
| | |
|
Male
|
134
|
55.1
|
|
Female
|
109
|
44.9
|
|
Age
| | |
|
≤49 years
|
56
|
23.0
|
|
50-60 yeas
|
72
|
29.6
|
|
>60 years
|
115
|
47.3
|
|
am
| | |
|
Rectum
|
111
|
45.7
|
|
Left colon cancer
|
77
|
31.7
|
|
Right colon cancer
|
55
|
22.6
|
|
Stage
| | |
|
II
|
140
|
57.6
|
|
III
|
103
|
42.4
|
|
Baseline neutrophil counts(×10
9
/L)
| | |
|
Mean(± SD)
|
4.27 ± 1.49
| |
|
Baseline lymphocyte counts(×10
9
/L)
| | |
|
Mean(± SD)
|
1.88 ± 0.59
| |
|
Chemotherapy-associated neutrophil counts
| | |
|
Neutrophil counts ≥ 1.5 × 109/L
|
153
|
63.0
|
|
Neutropenia < 1.5 × 109/L
|
90
|
37.0
|
|
Chemotherapy-associated lymphocyte counts
| | |
|
Lymphocyte counts ≥ 1.0 × 109/L
|
139
|
57.2
|
|
Lymphopenia < 1.0 × 109/L
|
104
|
42.8
|
